Infliximab for Injection
Efficacy and safety are equivalent to the original drug (Johnson & Johnson/Merck & Co.
The first infliximab biosimilar marketed in China
Infliximab for Injection (Reminton), a recombinant anti-TNF-alpha chimeric monoclonal antibody, was approved for marketing by the National Medical Products Administration (NMPA) on July 14, 2021. It is the first infliximab biosimilar marketed in China. Taking advantage of CHO cell expression system, Remin_x005f ton has been proved with good efficacy, better safety, and lower immunogenicity in clinical studies.
Indications:
Crohn's disease in adults and children over 6 years of age, stulizing Crohn's disease,
ulcerative colitis in adults, ankylosing spondylitis, rheumatoid arthritis, and psoriasis.
Recommended reading
Related products
-
The Latest 5-in-1 Car Jump Starter and Tire Inflator
Contact UsThis innovative device combines four essential functions in one compact unit, ensuring you’re well-equipped for any roadside emergency or outdoor adventure.
-
Paclitaxel for Injection(Albumin-Bound)
Contact UsAlbumin-bound paclitaxel takes the advantage of nanotechnology to combine the drug substance with human albumin to generate nanoparticles with improved solubility
-
Metal cloths
Contact UsYancheng Zhongming New Materials Co., Ltd. is located in Yancheng City, Jiangsu Province.
-
PGA temporary plugging agent
Contact UsPGA fully degradable temporary plugging agent is temporary plugging agent developed mainly with degradable materials to meet the needs of oil fields under various temperatures and working conditions.
Reviews
There are no reviews yet.